PET Study in Patients With Non-Hodgkin Lymphoma

Completed

Conditions studied: Lymphoma

In brief

RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well it predicts outcomes in patients who have undergone high-dose chemotherapy and autologous stem cell transplant for non-Hodgkin lymphoma.

Key facts

Study ID

NCT00712556

Run by

Vanderbilt-Ingram Cancer Center

People needed

55

Starts

2008-05-01

Expected to finish

2009-03-01

Last updated by the study team

2013-02-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DISEASE CHARACTERISTICS:
• Diagnosis of non-Hodgkin lymphoma
• Has undergone high-dose chemotherapy followed by autologous stem cell transplantation at Vanderbilt University between March 1997 and August 2005
• Has undergone fluorine 18-fludeoxyglucose PET within 70 days prior to and/or at approximately 30 days and 100 days after high-dose chemotherapy and autologous stem cell transplantation

You may not qualify if…

• PATIENT CHARACTERISTICS:
• Not specified
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics

Where it is running

• Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center at Franklin — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.